Although all T lymphocytes express antigen-specific receptors, there is increasing evidence that a population of blood T cells are "naive" in that they respond poorly to recall antigens, while other blood T lymphocytes are "memory" cells in that they proliferate readily in response to recall antigens, function efficiently as immune effector cells, and express surface molecules involved in antigen presentation and adhesion to endothelial cells and extracellular matrix components (1-5). The populations of "naive" and "memory" T cells are defined by the expression of the family of CD45 leukocyte common antigens coded by a single 130 kb, 33 exon gene (6) . The CD45 gene uses differential splicing to generate multiple mRNA transcripts that direct the synthesis of 220, 205, 200, 190, and 180 kD glycoproteins (7-12) . While the 220 and 205 kD glycoproteins are expressed on the surface of "naive" T cells and are detected by the 2144 mAb, the 180 kD glycoprotein is expressed only on "memory" T cells and is detected by the UCHL1 antibody (11-14) . Relative to the 33 exon CD45 gene, the mRNA transcript coding for the 220 kD 2144 + protein contains the sequence information of all 33 exons, while the transcript coding for the 205 kD 2144 + protein is missing residues coded by exon VI (12, 13) . In contrast, the CD45 mRNA transcript coding for the 180 kD UCHL1 + protein is missing exons IV, V,.
normal tissues chronically exposed to antigens, i .e ., T cells present in such tissues should be biased toward relatively more "memory" cells than present in blood .
The present study was directed toward evaluating the relative proportions of "naive" and "memory" T cells on the epithelial surface of the normal lower respiratory tract, a site constantly exposed to environmental antigens (21) . With the knowledge that "memory" T cells accumulate in areas of chronic inflammation (15) (16) (17) (18) (19) , we hypothesized that the population of T cells on the epithelial surface of the normal lung should be dominated by "memory" T cells . As a control, the observations in normal lung were compared with the T cell populations on the epithelial surface of the lower respiratory tract in chronic beryllium disease, a chronic T cell-mediated inflammatory lung disease caused by an exaggerated response to a specific antigen, beryllium (22) (23) (24) . Evaluation of 2H4 + and UCHL1 + surface antigen expression by flow cytometry, together with quantitative analysis of specific forms of CD45 mRNA transcripts, demonstrates that the T cell populations on the epithelial surface of the lung in both groups of individuals are dominated by T lymphocytes expressing the UCHL1 surface glycoprotein and containing CD45 mRNA transcripts missing exons IV, V, and VI . Thus, the T cells on both normal and chronically inflamed lung epithelial surface are dominated by "memory" type cells .
Materials and Methods
The study population included 10 normal nonsmokers (age 32 ± 3 yr) ; all had normal chest x rays, and pulmonary function, and none had history of pulmonary disease . The population of individuals with chronic beryllium disease included 8 individuals (6 nonsmokers and 2 smokers ; age 39 ± 3 yr), in whom the diagnosis was established using standard criteria (22) (23) (24) . None of the patients were taking any medications at the time of evaluation . All data are presented as mean ± SEM, and all statistical comparisons were made using the twotailed Student's t-test or the paired t-test, as appropriate . Logarithmic transformation was used to reduce the inequality of variance (25) .
Source of T Lymphocytes. Blood mononuclear cells were obtained by venipuncture, and lung mononuclear cells were obtained by bronchoalveolar lavage (26) . The volume of bronchoalveolar lavage fluid recovered in the normals was 57 ± 2°of that infused and 59 ± 2% in individuals with chronic beryllium disease . The amount of epithelial lining fluid (ELF)' recovered was quantified by the urea method (27) . For the normals, 25 ± 3 x 10' cells/Al ELF were recovered, including 78 t 6% alveolar macrophages, 17 ± 4% lymphocytes, 1 t lofo neutrophils, and 0% eosinophils . For the individuals with chronic beryllium disease, the total recovery was 53 ± 25 x 10'/ul ELF, including 34 t 5% alveolar macrophages, 66 ± 6% lymphocytes, 1 ± 1% neutrophils and I ± 1% eosinophils. Blood and lung T cells were purified using nylon wool columns (28) ; the resulting purity as assessed by the pan T cell antibody Leu5 (CD2 ; Becton Dickinson & Co., Mountain View, CA) was always >85% (see below for details of analysis) . T cell subsets were purified by FAGS (see below) .
Immunofluorescence, Flow Cytometry, and Cell Sorting.
The phenotype of lung and blood T cells was determined by immunofluorescence and flow cytometry (FAGS IV; Becton Dickinson & Co.) as previously described (28) [12, 29, 30] ; Coulter Immunology, Hialeah, FL), UCHLI (detecting the CD45 180 kD protein [12, 14) ; Dako Corp ., Santa Barbara, CA) . Isotype-matched unconju-' Abbreviations used in this paper: ELF, epithelial lining fluid ; PCR, polymerase chain reaction ; PE, phycoerythrin ; RT, reverse transcriptase . gated, FITC-or PE-conjugated IgG (Becton Dickinson & Co.) were used as controls. To determine the proportions of lung and blood T cells expressing CD45 205, 220 kD and CD45 180 kD surface proteins, T cells were double stained with Leu4-PE and 2H4 or UCHLI in conjunction with a FITC-conjugated goat anti-mouse antibody (Becton Dickinson & Co.) and analyzed with the FACS IV as previously described (28) . Distributions of 2H4 and UCHLI fluorescence intensity on blood CD3' T cells were analyzed on FACS fluorescence histograms using a curve-fitting program (COTFIT; B. Murphy, Carnegie-Mellon University, Pittsburgh, PA) to determine the lower confidence limit (mean t 2 SD) of the 2H4`or UCHLI' peaks; using this parameter, the percentages of "bright" 2H4' (cells with a specific fluorescence intensity higher than the lower confidence limit) and bright UCHLI`T cells were quantified in blood and lung.
Blood T cell subsets were purified by FACS into CD2'2H4' T cells and CD2'2H4-T cell populations using the FACS IV as previously described (28) . The purity of the resulting T cell populations was assessed by analysis of an aliquot of the sorted cells (2H4' cells: >99 ,70 Leu5', and >98% 2H4' ; 2H4' T cells: >99% Leu5', and <1% 2H4').
Polymerase Chain Reaction (PCR) Amplification and Southern Analysis of CD45 mRNA Transcripts. The various species of CD45 mRNA transcripts in blood and lung T cells generated by alternate splicing of the primary transcription product of the CD45 gene were evaluated by obtaining mRNA from purified T cells and T cell subpopulations, converting the mRNA to cDNA with reverse transcriptase (RT), and then amplifying the specific cDNAs using PCR (31, 32) and CD45-specific oligonucleotide primers. To accomplish this, RNA was extracted from the T cells using guanidine isothiocyanate cell lysis and purified by cesium chloride gradient centrifugation (33) . When the number of cells was limited to 10 6, RNA was extracted by NP40 cell lysis in the presence of ribonuclease inhibitor (RNAsin, 0.2 U/Ftl; Promega Biotec, Madison, WI) followed by enzymatic digestion of contaminating DNA (DNAse 5 U/ml ; RQl Promega Biotec) and phenol/chloroform extraction in the presence of 150 Ag/ml carrier tRNA (Bethesda Research Laboratories, Gaithersburg, MD) (34) .
To convert T cell mRNA into cDNA, single-stranded DNA complementary to CD45 exons I through X was synthesized by primer extension using a CD45 exon X-specific oligonucleotide primer ("CD45 X," 5' ATGTAACTGAAACTTTTC 3; see Fig. 1 ) and AMV reverse transcriptase (Boehringer Mannheim Biochemicals, Indianapolis, IN) in 20 t,l of RT buffer (50 mM Tris pH 8.3, 8 mM MgCI, 30 mM KCI, 0.3 mM dithiothreitol). All oligonucleotides were synthesized using an automated DNA synthesizer (Applied Biosystems, Inc., Foster City, CA) according to protocols supplied by the manufacturer and purified using Sephadex G 25 chromatography (PD10; Pharmacia Fine Chemicals, Piscataway, NJ). To amplify CD45-specific derived cDNAs, primers were used that would amplify all cDNA fragments derived from the differentially spliced CD45 mRNA transcripts . These CD45-specific primers included the 5' primer "CD45 11" that annealed to exon II (5' ATGTATTTGTGGCTTAA-ACTCTTG 3') and the 3' primer "CD45 IX" that annealed to exon IX (5' GCAGTACAT GAATTATGAGATATGG 3; see Fig. 1 for location of primers) . Because all CD45 transcripts are amplified by these primers, DNA products of variable size (376-870 bp) representing all different CD45 mRNA species should be obtained (Fig. 1) . Since all T cells express CD45 gene products (1) (2) (3) (4) (5) , this strategy allowed amplification of all CD45 mRNA species from all T cells, permitting quantitative evaluation of the expression of exon IV-positive CD45 mRNA (CD45R-IV/2H4') and exon IV, V, VI-negative CD45 mRNA (CD45R-0/UCHLI') transcripts using probes specific for each set of transcripts.
To accomplish this, PCR was performed using Taq polymerase (GeneAmp ; Cetus Corp., Emeryville, CA) in combination with the CD45-specific primers (2 .5 AM each) under standard conditions using the Thermal cycler (Perkin Elmer-Cetus) for 10 cycles (35) . A fixed aliquot (5%) of the PCR product was then further amplified for 30 cycles. Eight different CD45 mRNA species are generated by the alternate splicing of the primary gene transcript (6) (7) (8) (9) (10) (11) (12) (13) . In order to identify the three PCRamplified DNA fragments corresponding to the mRNAs coding for the 2H4' and the UCHL-1' proteins, the PCR products were evaluated by Southern blotting analysis using a panel of four exon-specific genomic probes and exon-exon junction-specific synthetic oligonucleotide probes . The PCR products (10% of the reaction medium) were size fractionated on 2.5% agarose gels (1 .5% NuSieve agarose (6) . Shown are the 5' region encompassing exons I-X, and the 3' exon XXXIII ; only exons IV-VI are involved in alternative splicing (7) (8) (9) (10) (11) . Below the gene is indicated the CD45-specific oligonucleotide primer used for cDNA synthesis ("CD45-X" cDNA primer ; complementary to exon X) and the 5' and 3' primers used for PCR amplification (5' primer "CD45I1" and 3' primer "CD45IX;" complementary to exon II and IX, respectively). Below the primers are shown the expected PCR products amplified from CD45R-IV/2H4' mRNA transcripts (870 and 720 bp) and CD45R0/UCHLI' mRNA transcripts (370 bp). Shown above the gene are the DNA probes used for Southern analysis of PCR-amplified CD45 mRNA, including the "III VII probe" to detect CD45R-0/UCHLI' mRNA transcripts; "III-IV probe" to detect CD45RIV/2114' transcripts ; "IV probe" to detect CD45R-IV/2114' transcripts; and a "IX probe" to detect all CD45 mRNA transcripts.
[Polysciences, Inc., Warrington, PA), 1% agarose, 1x TBE buffer [89 mM Tris-HCl, pH 8 .3, 89 mM boric acid, 2 mM EDTA]) and transferred to nylon membranes (Zetaprobe ; Biorad Laboratories, Richmond, CA) using 0.4 M NaOH (36) for hybridization with specific probes . The CD45-specific probes included (see Fig. 1 for location): (a) probe IX, pan CD45-specific exon IX, which is not spliced in any CD45 mRNA species (Eco RI/Hind III fragment of the genomic DNA clone pSP6 .LCA .204C; M . Streuli, Dana Farber Cancer Institute, Boston, MA [ll]); (b) probe IV, a probe encompassing exon IV specifically identifying CD45 mRNA species comprising exon IV (CD45R IV) coding for the 2114' gene product (11-13) (Bgl II/Bgl II fragment of the genomic DNA clone pSP6 .LCA204A ; M. Streuli [ll]); (c) "probe III-IV;" a probe encompassing the junction of exons III to IV, and thus CD45R-IVspecific (a synthetic 18-mer [5' TCCCCCACTGGATTGACT 3'] that is complementary to the exon III to exon IV junction sequence of the 2114* cDNA clone LCA.6 [11, 13] ) ; and (d) "probe IIIVII ;" a probe encompassing the exon III to exon VII junction and thus specific for the mRNA species generated by complete splicing of exons IV, V, VI (CD45R 0) coding for the UCHLI' gene product (11) (a synthetic 18-mer [5' TCCCCCACTGATGCCTAC 3] complementary to exon IIIVII junction sequence of the UCHLI' CD45 cDNA clone LCA.1 [11, 12] ) . The genomic probes were labeled with [s2P]CTP (200 ACi/pg DNA) by nick translation (37) . Oligonucleotide probes were end-labeled with ["P]ATP (400 ttCi/FAg DNA) and T4 polynucleotide kinase (Bethesda Research Laboratories) . The probes were purified by Sephadex G 25 chromatography (37) . Filter hybridization and autoradiography were performed using standard methods (36) .
To validate the ability of these methods to quantify the levels of CD45-IV mRNA in blood and lung T cells, T cell RNA (CD45R-IV') was titrated in 20 Al of RT buffer, converted to cDNA, and amplified as above using PCR. Quantification was obtained with Southern analysis using the "probe IV" and laser densitometry.
To further evaluate whether the normal lung T cell populations are dominated by T cells expressing the CD45 gene in a fashion consistent with their UCHLl' surface phenotype (see Results), lung T cells were separated into single cells using the FACS IV equipped with a single cell deposition device (Becton Dickinson & Co.) (38) , with 8.26 Am beads (Polybeads ; Polysciences, Inc.) sorted on glass slides as a control. The cells were denatured (95°C, 5 min), the RNA was converted to cDNA (39) , and the various CD45' mRNA transcripts were analyzed using specific primers as described above. "memory" UCHLI' phenotypes are similar (p > 0.1), the lung T cell population was dominated by "memory" UCHLl' T cells, in striking excess of the 2H4+ T cells (p < 0.01) . CD45 mRNA Expression by 2H4 and 2H4 Blood T Cell Subpopulations. To analyze the expression of the CD45 mRNA forms by different T cell populations, PCR amplification of CD45 mRNA was used in conjunction with Southern analysis with a set of four genomic and oligonucleotide DNA probes that allowed specific identification of the mRNA transcripts coding for the CD45RIV/2114+ CD45 product and the CD45R0/UCHL1 + CD45 product (see Fig. 1 for location ofthe probes and expected sizes of amplified products). Evaluation of normal blood T cell RNA with "probe IX;' and exon IX-specific probe, identified several PCR products (ranging in size from 370 to 870 bp) corresponding to the various human CD45 mRNAs (at least five [7, 11] ) generated by alternate splicing of the primary CD45 gene transcript. Among them were identified the CD45RIV mRNA species coding for the 2H4+ proteins (870 and 720 by PCR products) as well as the CD45R0 mRNA species coding for the UCHLI' protein (370 by PCR product; Fig. 4, lane 1) . "Probe IV," an exon IV-specific probe identified the CD45RIV mRNAs (870 and 720 by PCR products) but not the CD45R0' 370 by product (lane 2). "Probe III-IV," an exon III-IV junction-specific probe, also identified the CD45RIV' 870 and 720 by products (lane 3). In contrast, "probe III-VII'" an exon IIIVII junction-specific, probe identified only the CD45R-0+ 370 by product (lane 4) .
Results

Expression of CD45 Surface Proteins by
To demonstrate that differential T cell CD45 expression in "naive" and "memory" T cells at the mRNA level correlates with the 2H4+ and UCHLI' surface protein phenotypes, respectively, CD45RIV' and CD45R0' mRNA levels were evaluated in purified 2114 + T cells and 2114-purified T cells (Fig . 5) . Analysis of purified normal blood CD3 +2114+ T cells (Fig . 5 A) showed that they specifically expressed CD45RIV mRNA (870 and 720 by products [lane 1]), but no MOM mRNA transcripts (370 by product [lane 2]). In contrast, CD3 + 2114-T cells (Fig. 5 B) do not express CD45R-IV (870 and 720 by products [lane 3]), but did express CD45R-0 transcripts (370 by [lane 4] ). These observations are consistent with the concept that the specific CD45 RNA splicing patterns are different in the "naive" and "mem-FIGURE 4. Examples of Southern analysis of PCR-amplified blood T cell CD45 mRNA transcripts, T cell RNA was converted to cDNA, amplified using 5' CD45-II and 3' CD45-IX primers (see Fig. 1 ), and analyzed using "P-labeled probes as indicated for each lane. ory" T cell populations, and correlate directly with the CD45 220, 205, and the 180 kD surface proteins that identify two nonoverlapping populations of T cells (1, 5) .
Quantitative Evaluation of CD45 Expression in Normal Blood and Lung T Cells. The accuracy of the quantification of CD45R-IV' mRNA levels by PCR amplification was evaluated by preparing mixtures of a fixed amount of lung T cell mRNA (containing very little CD45RIV mRNA) with increasing amounts ofblood T cell mRNA (containing approximately equal amounts of CD45R-IV and CD45R-0 mRNA). Analysis of the amounts of PCRamplified CD45RIV' specific products demonstrated: (a) the methodology used could accurately quantify the amounts of specific CD45 mRNA transcript (correlation of input mRNA to specific output mRNA r = 0.99) ; and (b) the method was very sensitive, with as few as 1% of 2H4' T cells expressing CD45R-IV mRNA detectable (Fig. 6) .
Using this approach, PCR analysis of blood and lung T cell CD45 mRNA levels using exon IX-and exon IV-specific CD45 probes demonstrated that in contrast to blood where the two types of CD45 mRNA patterns are equally expressed, T cells in the normal lung are dominated by T cells expressing the CD45R-0 "memory" T cell-type mRNA transcripts (Fig. 7) . Strikingly, while blood T cells expressed the CD45RIV/2H4' mRNA transcripts (870 and 720 by CD45RIV+ fragments; Fig. 7 A, lane 1) , very little ofthis mRNA was present in lung T cells (lane 2). Quantitative assessment of these transcript levels demonstrated the blood T cells contained, on the average, 17-fold more CD45RIV mRNA per cell than did autologous lung T cells (Fig. 7 A, right; blood 35 t 13 density units, lung 2 ± 1 density units p < 0.01) . In contrast, both blood and lung T cells expressed the CD45R0/UCHLI' mRNA transcripts (370 by CD45R-0 product; Fig. 7 B) . Furthermore, the blood and lung T cells contained similar levels of the CD45R-0* transcripts (blood 13 t 2 density units, lung 14 t 2 density units; p > 0.7; Fig. 7 Quantification of CD45R-IV mRNA using cDNA synthesis, PCR amplification, Southern analysis with "probe IV," and laser densitometry. Data are shown as densitometry units. Ordinate: CD45R-IV mRNA levels (density units). Abscissa: blood T cell RNA (CD45R-IV*) concentrations (/~g/20 Wl of cDNA synthesis medium) added to a fixed amount (I kg/20 pl) of lung T cell RNA.
Cell Surface and mRNA Analysis of CD45 Expression by Bloodand Lung Tcells in Chronic
Beryllium Disease. Evaluation of the blood and lung T cells in individuals with chronic beryllium disease for the expression of CD45 isoforms using flow cytometry with the antibodies 2144 and UCHLI demonstrated that, similar to the normals, the lung T cell population was dominated by UCHLl+ "memory" T cells. While blood T cells from these individuals comprised proportions of "naive" 2144+ and "memory" UCHLV T cells that were similar to those observed in normals (2144+ 55 t 4% of CD3+, p > 0.5 compared with normal ; UCHLl + 40 t 4%, p > 0.05 compared with 2H4+, p > 0.1 compared with normal), the lung T cells were dominated by UCHL1 + "memory" T-cells (95 ± 2 % of CD3+ ; 2144+ 3 ± 1 % of CD3+, p < 0.01 UCHLI+ compared with 2144+) .
Consistent with these observations, PCR analysis of the levels of CD45 mRNA types in the T cells from the same individuals showed that T cells expressing the CD45R-0/UCHLI + mRNA accumulate in the lung of individuals with chronic beryllium disease. The lung T cells contained significantly less CD45RIV mRNA than blood T cells (blood 35 ± 4 densitometric units [1.2 t 0.3 log transformed units] ; lung 2 ± 1 densitometric units [0.4 ± 0.3 log transformed units] ; p < 0.01; Fig. 8 ], demonstrating that only a small proportion of lung T cells expressed the CD45 gene product in its "naive" nonspliced form . In contrast, lung T cells expressed significant levels of the CD45R-0 mRNA coding for the 180 kD UCHLl + protein (blood 20 ± 4 densitometric units (1 .3 ± 0 .1 log transformed units) ; lung 16 f 5 densitometric units (1.1 ± 0.1 log transformed units) ; p > 0.2; Fig. 8 ] indicating that these lung T cells express the CD45R0/UCHL1+ but not the CD45R-IV/2144+ mRNA, i.e., they express the "memory" T cell phenotype of the CD45 gene. Finally, quantification ofthe absolute numbers of T cells on the epithelial surface of the lungs of normals and individuals with chronic beryllium disease showed that in the lungs of these patients, chronic antigen-specific inflammation drives the accumulation of exaggerated numbers of "memory" T cells. In this regard, the concentration of CD3 + T cells present in the epithelial lining fluid of the lung of individuals with chronic beryllium disease was markedly increased (ninefold) compared with normal Evaluation of CD43 InRNA expression by blood and lung T cells of individuals with chronic beryllium disease. The analysis was identical to that for the normal individuals using the "IV probe" (CD45R-IV mRNA transcripts) and "IX probe" (CD45R-0 mRNA transcripts). Data are shown as arbitrary density units. Each data point represents a single individual . The lines connect the data from the same individual .
acteristics as it is found in the normal lung, but the inflammatory disease has a markedly increased total number of these cells .
Discussion
All T cells are characterized by their surface expression of the a/f or -Y/S antigen receptors (40) . The role ofthe , y/S receptor is not fully defined (41), but the TCR-a/0 clearly imparts upon T cells the ability to bind to antigens in the context of major histocompatibility molecules of class I (cytotoxic T cells) or class II (helper T cells) (42) . While all T cells have the potential to bind to specific antigens (40, 42) , it has become clear that T cells can be classified into two populations that respond to anti-
Quantification of the numbers of CD'2H4' "naive" T cells and CD3'UCHL1' . memory" Tcells on the epithelial surfaceof the lower respiratory tract of normals and individuals with chronic beryllium disease. The analysis was by flow cytometry with the antibodies Leu4 (CD3), 2H4 (CD45R-IV'), and UCHLI (CD45R-0') as indicated in' gens differently (1-4, 43) . "Naive" T cells do not respond well to recall antigens (1-4) , but do proliferate to some extent in response to anti-CD3e chain antibodies in the presence of IL-2 (44) or factors released by CD4+ Tcells (45) . In contrast, "memory" T cells of either the CD4+ and the CD8' subsets respond to recall antigens (46, 47) , proliferate strongly following CD3e stimulation (43), and do not require exogenous IL-2 (43-45), characteristics of T cells competent to initiate*immune responses to recall antigens . Current concepts hold that postthymic T cells with the "naive" T cells phenotype undergo further differentiation to become "memory" T cells, a process that entails enhanced expression of a number of adhesion molecules such as CD2, LFAI, and CDW29, the loss of surface CD45/2H4+ proteins, and the acquisition of the expression of CD45/UCHLI + proteins (1-5, 48, 49 ). In the context that tissues such as the epithelial surface of the lung are chronically exposed to a variety of antigens, the present study was directed toward defining the status ofthe T cell populations on the pulmonary epithelial surface in regards to their state of differentiation as "naive" or "memory" T cells, i.e., whether the normal tissue T cell population at a site chronically exposed to antigens is specialized in responding to recall antigens, or is as heterogeneous as are blood T cells.
Interestingly, we found that the population of T cells in the normal lung are dominated by CD45R-0 + , UCHLV "memory" T cells. Furthermore, comparison of T cell high density expression of CD45 2114' and UCHLV proteins ("bright" 2114' and UCHLV cells) with the expression of specific CD45 mRNA transcripts showed that, like the two populations of T cells in the blood, these two populations in the lung express alternative, nonoverlapping gene programs, i.e., 2114+ T cells do not express the CD45R0 mRNA and vice versa. The observations with the normal lung T cells suggest that the T cells that compartmentalize to and dominate the T cell populations on the lung epithelial surface are already differentiated, "memory" T cells. Several lines of evidence support this concept :
(a) Combined flow cytometry and mRNA analysis demonstrated that most lung 2114 -UCHLI+ T cells expressed only the spliced CD45R-0 mRNA form, suggesting that the regulatory mechanism that directs tissue-specific splicing of CD45 RNA (50) (c) It is unlikely that lung T cell activation ofthe IL-2 gene and T cell proliferation drive normal lung T cells to switch from 2H4+ to UCHL1' in situ in the lower respiratory tract, since normal lung T cells are proliferating at very low rates (51) and are not expressing IL-2 mRNA (51, 52) . In addition, consistent with the concept that lung T cells are already differentiated, lung T cells express the very late activation surface antigen VLA1 in much larger proportions than early activation surface proteins such as the IL-2 receptor (53).
(d) "Memory" T cells are likely to migrate into the normal lung at a higher rate than "naive" T cells. In this regard, as a consequence of a higher surface density of CD2 and LFA-1 (3, 5, 19) , adhesion molecules that bind to the LFA3 and ICAM-1 intercellular adhesion ligands (54) , "memory" T cells have the increased ability of adhering to capillary endothelial cells and of negotiating tissues. Furthermore, because normal alveolar macrophages are capable of high levels of production of TNFa (55), a potent cytokine capable of upregulating LFA3 and ICAM1 expression in a number of cells (56) , lung exposure to airborne particles and antigens may contribute to activate the recruitment of significant numbers of differentiated "memory" T cells to the lung .
Together, these observations are relevant to the understanding of the normal immune response in the lung, in that they suggest that the lung is a "specialized" site of T cell response to recall antigens . These "memory" T cells have the potential of a prompt release of the macrophage-activating lymphokine IFN--y, and a prompt, significant response to T cell receptor stimulation by recall antigens (5, 43) . In the same context, the data are consistent with the concept that the lung epithelial surface may not be the site of primary immune responses. Although lower respiratory tract immunization can generate cytotoxic and IFN-.y-mediated recall immune responses (57, 58) , this may be secondary to the transport of antigen to lung lymph nodes by macrophages (59) rather than local T cell stimulation. Furthermore, experiments with local lung Bacillus Calmette-Guerin vaccinations have shown that local lung immunization may be less efficacious than other vaccination routes (60) , suggesting that T cell activation within the lymph nodes (a tissue that is rich in 2H4+ Tcells [61, 62] ) may be necessary for optimal immunization against new antigens .
Further support of the concept that "memory" T cells compartmentalize to antigenexposed tissues is provided by the observation that the chronic presence of a beryllium burden in the lower respiratory tract of individuals with chronic beryllium disease dramatically expands the numbers of UCHLI + T cells in the lung, i.e ., the beryllium-specific UCHLI + T cells, already present or recruited to the lungs, are stimulated in the local milieu to proliferate . These observations are consistent with studies with anti-CD45 and CDw29 antibodies, demonstrating that at sites of chronic inflammation such as leprosy skin lesions (63), tuberculosis pleural effusions (16) , and rheumatoid joint fluid (15, (17) (18) (19) , T cells are dominated by 2H4-/UCHL1 +/ 4B4+ (CDw29 +) T cells. This suggests that chronic exposure to antigens is characterized by the compartmentalization of larger numbers of "memory" type T cells in tissues (19) . The observations in chronic beryllium disease also support the concept that immune response of this disease is a normal, albeit an exaggerated response, i.e ., the exaggerated immune process results from a normal, although heightened response of compartmentalized antigen-specific "memory" T cells.
In conclusion, this study demonstrates that in the lung, a model of normal tissue chronically exposed to antigens, the local T cell population is dominated by "memory" 2H4-UCHLI`T cells. The observation is important to the understanding of tissue-lung immunity in two ways . First, it puts the concept of postthymic differentiation of "memory" T cells (1-5, 48, 49) in the context of the role of T cell populations in tissue immune responses (64, 65) . Second, by supporting and further defining the concept of the lung as an immune compartment, it is suggested that strategies for the evaluation of the immunoregulatory processes in chronic inflammatory lung disorders must be centered on evaluating "local" processes since evaluation of the blood will not yield a valid picture of the immune processes ongoing within the tissue. Finally, the finding that the normal lung is the site of a specialized population of T cells has important implications to chronic immune disorders of the lung. In this regard, in the context of a number of studies demonstrating that the 2H4' "naive" T cell population, but not the population of UCLH1' "memory" T cells, contains T cells capable of inducing suppressor T cells (30) , it is possible that persistent activation of sensitized helper T cells in the lung milieu (such as in individuals with chronic beryllium disease) may not be accompanied by local generation of a down regulatory T cell response, with the concomitant suppressor T cell activation (23) (24) (25) 66 ) .
Summary
Expression of alternatively spliced products of the CD45 leukocyte common antigen gene identifies two populations ofblood T cells : "naive" T cells (containing CD45R-IV mRNA transcripts, CD45 220, 205 kD surface proteins detected with antibody 2H4) that respond poorly to recall antigens, and "memory" T cells (containing CD45R-0 mRNA transcripts, expressing CD45 180 kD protein, detected with antibody UCHLI) that respond promptly to recall antigens. While blood contains approximately equal numbers of "naive" and "memory" T cells, it is known that UCHLI' "memory" T cells accumulate at sites of chronic inflammation . To test the concept that "memory" T cells are a feature ofthe T lymphocyte populations present in tissues chronically exposed to antigens in normals as well as in individuals with chronic inflammation, we evaluated T lymphocytes obtained from blood and the epithelial surface of the lower respiratory tract of normal individuals for the expression ofspecific CD45 surface protein isoforms and corresponding mRNA transcripts. Flow cytometric analysis of CD45 220, 205, and 180 kD surface proteins demonstrated that lung T cells of normals are dominated by UCHLI' "memory" cells (86 ± 2%) while autologous blood T cells have equal proportions of "memory" UCHL1' and "naive" 2H4' T cells . In addition, polymerase chain reaction analysis of CD45 mRNA transcripts revealed that the lung cells expressed CD45R0 mRNA transcripts but 17-fold fewer CD45RIV mRNA transcripts than autologous blood T cells (,6 < 0.01). The pattern of lung T cells being dominated by CD45R0 mRNA', UCHLl' "memory" T cells was also observed in individuals with chronic beryllium disease, an example of a chronic inflammatory disease in which antigen-specific T cells accumulate on the pulmonary epithelial surface . Like the normals, the lung T cells of the beryllium disease patients were dominated by CD45R-0 mRNA transcript', UCHLI', T cells. However, on a quantitative basis, the beryllium patients contained far greater numbers of T cells, i.e., the T cell populations on the surface of the normal and inflamed lung are similar in character ("memory" T cells) but differ in numbers (there are far more in the chronic inflammatory state) . Thus, T cell populations on the epithelial surface ofthe normal lung likely reflect the chronic exposure to a diverse set of antigens, with a pattern that is qualitatively similar to that observed among T cells accumulating in response to a single antigen .
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